Chugai Seiyaku Kabushiki Kaisha

Nissan Chemical Industries Limited

Chugai Seikayu Kabushiki Kaisha

Masateru Ohta

Haruhiko Sato

Takuya Shiraishi

Kazutaka Tachibana

Mitsuaki Nakamura

Hitoshi Yoshino

Hiromitsu Kawata

Naoki Okamoto

Yoshikazu Nishimura

Toru Esaki

Yoshiaki Isshiki

Yoshiyuki Furuta

Akemi Mizutani

Tomoya Kotake

Ikuhiro Imaoka

Masahiro Nagamuta

Wayne Wen Lai

Yoshiaki Watanabe

Takashi Emura

Shojiro Kadono

Kazuhiko Ohrai

Yoshiyuki Suzuki

Masahiro Sakaitani

Takanori Shimizu

Keishi Hayashi

Nobuaki Kato

Nobuya Ishii

Masataka Minami

Masami Hasegawa

Etsuro Onuma

Koji Toyama

Michiaki Adachi

Kenji Taniguchi

Akie Honma

Masakazu Sugiyama

The present invention relates to a compound represented by the following formula (1): wherein W, X, Y, R, R, R, R, m and n are as defined in the claims, or a pharmacologically acceptable salt thereof.

Spiroimidazolone derivative

An imidazole derivative represented by formula (I): wherein Q is: A is hydrogen, halogen, or a substituted or unsubstituted Calkyl group; E is independently selected from a Calkyl group; Rand Rare independently selected from Calkyls; Xand Xare independently selected from O and S; Y is selected from a substituted or unsubstituted arylene group and a substituted or unsubstituted divalent 5- or 6-membered monocyclic or 8- to 10-membered condensed heterocyclic group; Z is &#x2014;CON(&#x2014;Ra)&#x2014;, &#x2014;CO&#x2014;, &#x2014;OOO&#x2014;, &#x2014;NRa&#x2014;C(&#x2550;NH)NRb&#x2014;, &#x2014;NRa&#x2014;C(&#x2550;N&#x2014;CN)NRb&#x2014;, &#x2014;N(&#x2014;Ra)COO&#x2014;, &#x2014;C(&#x2550;NH)&#x2014;, &#x2014;SO&#x2014;, &#x2014;SON(&#x2014;Ra)&#x2014;, &#x2014;SONR&#x2014;, &#x2014;N(&#x2014;Ra)CO&#x2014;, &#x2014;N(&#x2014;Ra)CON(&#x2014;Rb)&#x2014;, &#x2014;N(COR)CO&#x2014;, &#x2014;N(&#x2014;Ra)SO&#x2014;, &#x2014;N(SOR)SO&#x2014;, &#x2014;N(&#x2014;Ra)&#x2014; or &#x2014;N(&#x2014;Ra)SON(&#x2014;Rb)&#x2014;; Ris independently a hydrogen atom, a hydroxyl group, or substituted or unsubstituted group selected from Calkyl group, heterocyclic group, aryl group, Ccycloalkyl group and Ccycloalkenyl group; or salt or prodrug thereof.

Imidazolidine derivative and use thereof

The present invention provides novel &#x3b1;-amino acid derivatives of formula (1): (wherein, R, R, R, R, X and Y are as defined in the claims) or pharmaceutically acceptable salts, prodrugs or solvates thereof. The derivatives of formula (1) have &#x3b2;ARK1 inhibitory activity and are useful for preventing or treating heart failure. Moreover, the derivatives of formula (1) also have antitumor activity, particularly dual inhibitory activity on Aurora kinase and CDK, and are useful for cell proliferative diseases such as cancer.

&#x3b1;-amino acid derivatives and medicaments containing the same as an active ingredient

The present invention provides a compound represented by formula (I):  A is cyano or the like; B is hydrogen, halogen, or the like; Xand Xare each independently selected from O and S; E is a Calkyl group; and R, R, Rand Rare each independently selected from a hydrogen atom and a C-Calkyl group, and a drug, a pharmaceutical composition containing the compound, and the like.

Imidazolidine derivatives

The present invention provides a compound represented by formula (I): [Formula 1] wherein n is an integer selected from 1 to 20, and Rand R, which may be the same or different, each represent a hydrogen atom, or a linear or branched C-Calkyl group, or a salt, a prodrug or a solvate thereof, as well as a drug, a pharmaceutical composition containing the compound, and the like.

A compound pf general formula (I):wherein, for example,

Antiandrogenic agent

Growing community of inventors

Gotenba, Japan

Masateru Ohta